BELLINGHAM
Cancer Incidence by Sex, 1993 - 1997
Expected and Observed Case Counts, with Standardized Incidence Ratios

| | Exp | <u>Obs</u> | SIR | | Exp | <u>Obs</u> | SIR | |
|----------------------|---------------|-------------|-------------------------|------------------------|-------|------------|-----|--|
| Bladder, Urina | <u>iry</u> | | Melanoma of Skin | | | | | |
| Male | 7.06 | 14 | 198 #+ | Male | 4.91 | 5 | 102 | |
| Female | 2.56 | 4 | NC* | Female | 3.99 | 4 | NC* | |
| Total | 9.62 | 18 | 187 #+ | Total | 8.90 | 9 | 101 | |
| Brain and Oth | er Central No | ervous Syst | <u>em</u> | Multiple Myeloma | | | | |
| Male | 2.85 | 3 | NC* | Male | 1.37 | 0 | NC* | |
| Female | 2.40 | 2 | NC* | Female | 1.25 | 1 | NC* | |
| Total | 5.25 | 5 | 95 | Total | 2.62 | 1 | NC* | |
| Breast | | | | Non-Hodgkin's Lymphoma | | | | |
| Male | 0.48 | 0 | NC* | Male | 6.50 | 10 | 154 | |
| Female | 49.00 | 57 | 116 | Female | 5.26 | 4 | NC* | |
| Total | 49.48 | 57 | 115 | Total | 11.77 | 14 | 119 | |
| Cervix Uteri | | | Oral Cavity and Pharynx | | | | | |
| | | | | Male | 5.42 | 4 | NC* | |
| Female | 3.51 | 3 | NC* | Female | 2.43 | 1 | NC* | |
| | | | | Total | 7.85 | 5 | 64 | |
| Colon / Rectun | <u>n</u> | | Ovary | | | | | |
| Male | 18.14 | 20 | 110 | | | | | |
| Female | 16.31 | 20 | 123 | Female | 6.06 | 6 | 99 | |
| Total | 34.45 | 40 | 116 | | | | | |
| Esophagus | | | | Pancreas | | | | |
| Male | 2.81 | 3 | NC* | Male | 2.87 | 6 | 209 | |
| Female | 0.84 | 0 | NC* | Female | 2.77 | 1 | NC* | |
| Total | 3.65 | 3 | NC* | Total | 5.65 | 7 | 124 | |
| Hodgkin's Dis | <u>ease</u> | | Prostate | | | | | |
| Male | 1.53 | 0 | NC* | Male | 45.80 | 46 | 100 | |
| Female | 1.17 | 0 | NC* | | | | | |
| Total | 2.70 | 0 | NC* | | | | | |
| Kidney and Re | enal Pelvis | | Stomach | | | | | |
| Male | 4.67 | 2 | NC* | Male | 3.13 | 1 | NC* | |
| Female | 2.70 | 4 | NC* | Female | 1.74 | 0 | NC* | |
| Total | 7.37 | 6 | 81 | Total | 4.87 | 1 | NC* | |
| <u>Larynx</u> | | | | <u>Testis</u> | | | | |
| Male | 2.86 | 2 | NC* | Male | 2.28 | 4 | NC* | |

| Female | 0.80 | 0 | NC* | | | | |
|-----------------------------------|-------|----|-------------------|--------------------------------------|--------|-----|-----|
| Total | 3.67 | 2 | NC* | | | | |
| Leukemia | | | | Thyroid | | | |
| Male | 3.47 | 1 | NC* | Male | 1.12 | 0 | NC* |
| Female | 2.58 | 0 | NC* | Female | 2.91 | 3 | NC* |
| Total | 6.04 | 1 | NC* | Total | 4.03 | 3 | NC* |
| Liver and Intrahepatic Bile Ducts | | | | Uteri, Corpus and Uterus, NOS | | | |
| Male | 1.59 | 2 | NC* | | | | |
| Female | 0.59 | 0 | NC* | Female | 9.36 | 15 | 160 |
| Total | 2.18 | 2 | NC* | | | | |
| Lung and Broa | nchus | | All Sites / Types | | | | |
| Male | 24.48 | 21 | 86 | Male | 154.12 | 154 | 100 |
| Female | 18.57 | 14 | 75 | Female | 146.85 | 149 | 101 |
| Total | 43.05 | 35 | 81 | Total | 300.96 | 303 | 101 |
| | | | | | | | |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels